-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on Immunovant, Raises Price Target to $22

Benzinga·01/08/2026 17:04:56
Listen to the news
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $16 to $22.